MUC16 and neoplasm: Patients with a PFI of <12 months more frequently presented with preoperative CA125 levels of ≥114.5 U/mL, advanced-stage disease, RD sized ≥1 cm, poor response to front-line chemotherapy, tumour resection following the first relapse, and post-progression chemotherapy regimens other than platinum–paclitaxel doublets.